Monopar Historical Income Statement

MNPR Stock

USD 20.10 0.39 1.98%

Historical analysis of Monopar Therapeutics income statement accounts such as Total Operating Expenses of 7.5 M can show how well Monopar Therapeutics performed in making a profits. Evaluating Monopar Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Monopar Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

About Monopar Income Statement Analysis

Monopar Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Monopar Therapeutics shareholders. The income statement also shows Monopar investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Monopar Therapeutics Income Statement Chart

At this time, Monopar Therapeutics' Selling General Administrative is relatively stable compared to the past year. As of 11/25/2024, Total Other Income Expense Net is likely to grow to about 450.5 K, while Operating Income is likely to drop (9.3 M).

Interest Expense Selling General Administrative Net Income From Continuing Ops Research Development Total Operating Expenses Total Other Income Expense Net

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Monopar Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.At this time, Monopar Therapeutics' Selling General Administrative is relatively stable compared to the past year. As of 11/25/2024, Total Other Income Expense Net is likely to grow to about 450.5 K, while Operating Income is likely to drop (9.3 M).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	9.1M	10.5M	8.8M	7.5M
Research Development	6.5M	7.6M	5.6M	5.3M

Total Operating Expenses Research Development

Monopar Therapeutics income statement Correlations

	Selling General Administrative	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Net Interest Income	Interest Income	Other Operating Expenses	Ebitda	Tax Provision	Depreciation And Amortization	Income Tax Expense	Gross Profit	Selling And Marketing Expenses
Selling General Administrative		-0.34	-0.38	-0.25	0.2	0.28	-0.31	0.93	-0.31	0.96	0.96	0.3	0.36	0.95	0.88	0.72	-0.95	-0.95
Operating Income	-0.34		1.0	0.95	-0.98	-1.0	1.0	-0.42	1.0	-0.41	-0.41	-1.0	0.76	-0.32	-0.35	-0.51	0.32	0.32
Net Income From Continuing Ops	-0.38	1.0		0.94	-0.97	-0.99	1.0	-0.46	1.0	-0.45	-0.45	-1.0	0.72	-0.36	-0.38	-0.54	0.36	0.36
Ebit	-0.25	0.95	0.94		-0.92	-0.95	0.95	-0.43	0.94	-0.36	-0.36	-0.94	0.76	-0.23	-0.42	-0.38	0.24	0.24
Research Development	0.2	-0.98	-0.97	-0.92		0.98	-0.98	0.27	-0.98	0.27	0.27	0.99	-0.83	0.2	0.21	0.39	-0.19	-0.19
Total Operating Expenses	0.28	-1.0	-0.99	-0.95	0.98		-1.0	0.37	-1.0	0.36	0.36	1.0	-0.79	0.28	0.29	0.47	-0.24	-0.24
Income Before Tax	-0.31	1.0	1.0	0.95	-0.98	-1.0		-0.4	1.0	-0.39	-0.39	-1.0	0.77	-0.29	-0.32	-0.5	0.3	0.3
Total Other Income Expense Net	0.93	-0.42	-0.46	-0.43	0.27	0.37	-0.4		-0.4	0.98	0.98	0.38	0.23	0.88	0.96	0.59	-0.88	-0.88
Net Income	-0.31	1.0	1.0	0.94	-0.98	-1.0	1.0	-0.4		-0.39	-0.39	-1.0	0.77	-0.29	-0.32	-0.5	0.3	0.3
Net Interest Income	0.96	-0.41	-0.45	-0.36	0.27	0.36	-0.39	0.98	-0.39		1.0	0.37	0.26	0.9	0.89	0.62	-0.91	-0.91
Interest Income	0.96	-0.41	-0.45	-0.36	0.27	0.36	-0.39	0.98	-0.39	1.0		0.37	0.26	0.9	0.89	0.62	-0.91	-0.91
Other Operating Expenses	0.3	-1.0	-1.0	-0.94	0.99	1.0	-1.0	0.38	-1.0	0.37	0.37		-0.78	0.29	0.31	0.49	-0.28	-0.28
Ebitda	0.36	0.76	0.72	0.76	-0.83	-0.79	0.77	0.23	0.77	0.26	0.26	-0.78		0.34	0.26	0.0	-0.34	-0.34
Tax Provision	0.95	-0.32	-0.36	-0.23	0.2	0.28	-0.29	0.88	-0.29	0.9	0.9	0.29	0.34		0.83	0.69	-0.8	-0.8
Depreciation And Amortization	0.88	-0.35	-0.38	-0.42	0.21	0.29	-0.32	0.96	-0.32	0.89	0.89	0.31	0.26	0.83		0.55	-0.83	-0.83
Income Tax Expense	0.72	-0.51	-0.54	-0.38	0.39	0.47	-0.5	0.59	-0.5	0.62	0.62	0.49	0.0	0.69	0.55		-0.68	-0.68
Gross Profit	-0.95	0.32	0.36	0.24	-0.19	-0.24	0.3	-0.88	0.3	-0.91	-0.91	-0.28	-0.34	-0.8	-0.83	-0.68		1.0
Selling And Marketing Expenses	-0.95	0.32	0.36	0.24	-0.19	-0.24	0.3	-0.88	0.3	-0.91	-0.91	-0.28	-0.34	-0.8	-0.83	-0.68	1.0

Click cells to compare fundamentals

Monopar Therapeutics Account Relationship Matchups

Monopar Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	98.9K	81.9K	24.0K	21.2K	24.4K	23.2K
Selling General Administrative	2.4M	2.4M	2.6M	2.9M	3.2B	3.4B
Operating Income	(4.3M)	(6.5M)	(9.1M)	(10.5M)	(8.8M)	(9.3M)
Net Income From Continuing Ops	(4.2M)	(6.3M)	(9.1M)	(10.5M)	(9.5M)	(10.0M)
Ebit	(4.3M)	(13.1M)	(9.1M)	(10.5M)	(8.4M)	(8.8M)
Research Development	2.0M	4.1M	6.5M	7.6M	5.6M	5.3M
Total Operating Expenses	4.3M	6.5M	9.1M	10.5M	8.8M	7.5M
Income Before Tax	(4.2M)	(6.3M)	(9.1M)	(10.5M)	(8.4M)	(8.8M)
Total Other Income Expense Net	98.9K	204.3K	24.0K	21.2K	429.0K	450.5K
Net Income Applicable To Common Shares	(3.2M)	(4.2M)	(6.3M)	(9.1M)	(8.2M)	(8.6M)
Net Income	(4.1M)	(6.2M)	(9.1M)	(10.5M)	(8.4M)	(8.8M)
Net Interest Income	98.9K	81.9K	24.0K	21.2K	343.6K	360.8K
Interest Income	98.9K	81.9K	24.0K	21.2K	343.6K	360.8K
Other Operating Expenses	4.3M	6.5M	9.1M	10.5M	8.8M	8.3M
Ebitda	(4.3M)	(6.6M)	(9.1M)	(10.5M)	429.0K	450.5K
Depreciation And Amortization	4.3K	6.5M	48.0K	21.2K	8.8M	9.3M
Income Tax Expense	(98.9K)	(81.9K)	(24.0K)	(21.2K)	(8.8K)	(9.3K)

Pair Trading with Monopar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Monopar Stock

0.86	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.82	AGL	agilon health	Pair Corr
0.81	NKTX	Nkarta Inc	Pair Corr
0.79	MTEM	Molecular Templates	Pair Corr
0.78	ME	23Andme Holding	Pair Corr

The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.

The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Monopar Historical Income Statement

About Monopar Income Statement Analysis

Monopar Therapeutics Income Statement Chart

Interest Expense

Total Operating Expenses

Monopar Therapeutics income statement Correlations

Monopar Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Monopar Therapeutics income statement Accounts

Pair Trading with Monopar Therapeutics

Moving against Monopar Stock

Additional Tools for Monopar Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income From Continuing Ops	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Other Operating Expenses	+ 1.0	Total Operating Expenses

Other Operating Expenses	- 1.0	Net Income
Other Operating Expenses	- 1.0	Income Before Tax
Net Income	- 1.0	Total Operating Expenses
Income Before Tax	- 1.0	Total Operating Expenses
Other Operating Expenses	- 1.0	Net Income From Continuing Ops
Other Operating Expenses	- 1.0	Operating Income